603707.SH
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.06
−0.74%Year over year
Reported trailing growth
- Revenue
- +6.0%
- EBITDA
- —
- EBIT
- -20.5%
- EPS
- -17.4%
- Free cash flow
- +42.6%
- Operating cash flow
- +4.4%
Forward estimates
Based on analyst estimates
- Revenue
- -0.7%
- EBITDA
- +35.5%
- EPS
- +24.0%
Three-year CAGR
- Revenue
- +2.4%
- EBITDA
- -10.4%
- EBIT
- -15.8%
- Net income
- -18.9%
- EPS
- -18.7%
- Free cash flow
- +70.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026